TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11735786

Group type: EXPERIMENTAL
Intervention: Trabeculectomy (first or second AGIS intervention)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Trabeculectomy without complications
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Trabeculectomy with complications
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Marked inflammation as a postoperative complication
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Flat anterior chamber as a postoperative complication
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Age at study entry
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 591
Study: 9240286

Group type: EXPERIMENTAL
Intervention: Acute form of SF-36 Health Survey (one-week recall)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard form of SF-36 Health Survey (four-week recall)
Number of subjects: 142
Study: 8370085

Group type: EXPERIMENTAL
Intervention: Floating (F) hydrophilic matrix capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfloating (NF) hydrophilic matrix capsules
Number of subjects: 0
Study: 3535474

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg orally twice a day (or 400 mg if weight > 80 kg) from 36 hours after surgery until discharge (usually on the seventh day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no beta-blocking drugs)
Number of subjects: 100
Study: 11522432

Group type: EXPERIMENTAL
Intervention: Smoking (48 smoking alcoholics)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nonsmoking (15 nonsmoking alcoholics)
Number of subjects: 63
Study: 31136283

Group type: EXPERIMENTAL
Intervention: Serum Trimethylamine N-Oxide Concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (baseline CSPPT participants who did not develop stroke during follow-up)
Number of subjects: 0
Study: 29044968

Group type: EXPERIMENTAL
Intervention: DUT‐TAM FDC therapy (dutasteride 0.5 mg and tamsulosin 0.4 mg)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 27154875

Group type: EXPERIMENTAL
Intervention: Wii Fit training (1 hour, 2 days per week, during 8 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional balance exercises
Number of subjects: 38
Study: 24520784

Group type: EXPERIMENTAL
Intervention: qi benefiting stasis removing method (QBSRM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine Western therapy (Control)
Number of subjects: 40
Study: 22616853

Group type: EXPERIMENTAL
Intervention: Combination of controlled-release melatonin and cognitive-behavioural therapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Controlled-release melatonin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo drug treatment
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination treatment group
Number of subjects: 160
Study: 19705134

Group type: EXPERIMENTAL
Intervention: Colchicine, 1 mg QD for 2 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 60
Study: 18029492

Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrate (JPC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 15702262

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98

Group type: COMPARATOR
Intervention: General stretching
Number of subjects: 98
Study: 12236606

Group type: EXPERIMENTAL
Intervention: Drama-group therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Curriculum-studies control
Number of subjects: 122

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 122
Study: 10426340

Group type: EXPERIMENTAL
Intervention: Exercise training (3 times per week for 6 months) in group A
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maximal oxygen consumption improvement in group A
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exercise testing duration improvement in group A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group B (untrained hemodialysis patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group C (nonuremic sedentary persons)
Number of subjects: 60
Study: 7769058

Group type: EXPERIMENTAL
Intervention: Normegon
Number of subjects: 158

Group type: COMPARATOR
Intervention: Metrodin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 158
Study: 2186647

Group type: EXPERIMENTAL
Intervention: Papaveretum and scopolamine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Temazepam
Number of subjects: 50
Study: 116373

Group type: EXPERIMENTAL
Intervention: Cefaclor 2, 3, or 4 g with or without 1 g probenecid, administered as single daily doses for three days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cefaclor 3 or 4 g
Number of subjects: 90
Study: 30264170

Group type: EXPERIMENTAL
Intervention: Rehydration during exercise using water (H1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rehydration during exercise using an isotonic sports drink (H2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No rehydration during exercise (NH1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No rehydration during exercise (NH2)
Number of subjects: 20
Study: 29614468

Group type: EXPERIMENTAL
Intervention: Crossover foot (Össur Cheetah Xplore)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Energy storing foot (Össur Variflex)
Number of subjects: 27
Study: 26746850

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol solution (OMS)
Number of subjects: 481

Group type: COMPARATOR
Intervention: Vaginal dinoprostone
Number of subjects: 481
Study: 25257907

Group type: EXPERIMENTAL
Intervention: High-speed video (HSV)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Videostroboscopy (VS)
Number of subjects: 7
Study: 22288893

Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO) 2.5 mg twice per day for 2 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO) 5 mg twice per day for 2 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (PLA) twice per day for 2 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO)
Number of subjects: 36
Study: 20615252

Group type: EXPERIMENTAL
Intervention: Non-surgical spinal decompression via the DRX9000 for 6 weeks
Number of subjects: 30
Study: 17394959

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus N-acetylcysteine (N-AC) infusion started just before contrast injection and continued for 12 h after PCI
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard hydration protocol consisting of intravenous isotonic saline for 12 h after PCI
Number of subjects: 111
Study: 15637527

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg daily for 6 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily for 6 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Probenecid (2000 mg daily for 6 days)
Number of subjects: 12
Study: 12712059

Group type: EXPERIMENTAL
Intervention: Family-focused teamwork (TW) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard multidisciplinary diabetes care (SC)
Number of subjects: 100
Study: 10986827

Group type: EXPERIMENTAL
Intervention: 20 percent carbamide peroxide (CP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 7.5 percent hydrogen peroxide (HP)
Number of subjects: 24
Study: 8795770

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 33

Group type: COMPARATOR
Intervention: 1.0% carteolol
Number of subjects: 33

Group type: COMPARATOR
Intervention: 2.0% carteolol
Number of subjects: 33
Study: 1636805

Group type: EXPERIMENTAL
Intervention: Acute plus maintenance treatment with imipramine (18 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acute treatment with imipramine (6 months)
Number of subjects: 30
Study: 6394778

Group type: EXPERIMENTAL
Intervention: 45% BCAA enriched (low leucine) amino acid solution
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 25% BCAA amino acid solution
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 45% BCAA enriched (high leucine) amino acid solution
Number of subjects: 25

Group type: COMPARATOR
Intervention: 5% dextrose in water (control)
Number of subjects: 25
Study: 31455015

Group type: EXPERIMENTAL
Intervention: Virtual reality experience of partly open green space
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Virtual reality experience of closed green space
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Virtual reality experience of blue space and partly closed green space
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Closing eyes for relaxation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Virtual reality experience of six environmental types
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Preference for natural environments
Number of subjects: 120
Study: 30012175

Group type: EXPERIMENTAL
Intervention: exergaming + a-tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: exergaming + sham a-tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 24
Study: 26351393

Group type: EXPERIMENTAL
Intervention: Anal fistula plug (AFP) insertion
Number of subjects: 106

Group type: COMPARATOR
Intervention: Seton removal (control group)
Number of subjects: 106
Study: 24918122

Group type: EXPERIMENTAL
Intervention: Plant sterols claims (disease risk reduction claim, function claim, nutrient content claim)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Oat fibre claims (three claims related to OF)
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Taste great claim (control)
Number of subjects: 1431
Study: 22856593

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg by mouth twice a day for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (by mouth, same dosage and duration as zinc)
Number of subjects: 0
Study: 20216360

Group type: EXPERIMENTAL
Intervention: CR enhanced by SMT (stress management training) including relaxation training, cognitive restructuring, communication skills, and problem solving
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard exercise-based CR
Number of subjects: 150
Study: 17921373

Group type: EXPERIMENTAL
Intervention: High-fiber cereal (HF; 33 g insoluble fiber)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fiber cereal (LF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 0
Study: 16258291

Group type: EXPERIMENTAL
Intervention: Bilateral breast reduction (BBR) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 0
Study: 12195689

Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation of the calf
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation of the plantar muscles
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-stimulated lower extremity
Number of subjects: 49
Study: 9736552

Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) 70 mg in fasting state
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) 70 mg 1 hour before a meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) 70 mg 5 minutes after a high-fat breakfast
Number of subjects: 15
Study: 7802178

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microgram.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Midazolam 20 micrograms.kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 90
Study: 3055929

Group type: EXPERIMENTAL
Intervention: High Protein
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High Sucrose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High Starch
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 30998531

Group type: EXPERIMENTAL
Intervention: ATX-101
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29466361

Group type: EXPERIMENTAL
Intervention: Epicardial fat gain (EF gain) group (n = 65)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Epicardial fat decrease group (n = 33)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (EF gain and EF decrease)
Number of subjects: 98
Study: 26909845

Group type: EXPERIMENTAL
Intervention: Grape intake of 50 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grape intake of 100 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grape intake of 150 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g/day of grapes (control)
Number of subjects: 0
Study: 25259781

Group type: EXPERIMENTAL
Intervention: Health educator (HE) intervention in the intervention group (IG)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sports participation
Number of subjects: 165
Study: 22180445

Group type: EXPERIMENTAL
Intervention: Systematic neuropsychological approach
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional (functional) dressing practice
Number of subjects: 70
Study: 21143878

Group type: COMPARATOR
Intervention: GTP (500 mg GTP/day)
Number of subjects: 171

Group type: COMPARATOR
Intervention: TC exercise (60 min/session, 3 sessions/week)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: GTP + TC
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Placebo + TC
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 17275908

Group type: EXPERIMENTAL
Intervention: Intravitreal 10% C3F8 infusion at the end of surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: No intravitreal gas (Control)
Number of subjects: 61
Study: 16225724

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 160

Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 160
Study: 11898722

Group type: EXPERIMENTAL
Intervention: Aspirin conventional therapy: 125 mg 3 times a day for 16 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aspirin chronotherapy: 125 mg once a day for 16 days at 22 p.m.
Number of subjects: 30
Study: 10681809

Group type: EXPERIMENTAL
Intervention: Lentinan treatment for 2 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lentinan in vitro
Number of subjects: 44
Study: 7655202

Group type: EXPERIMENTAL
Intervention: Heparin sodium (+H)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No heparin (-H)
Number of subjects: 72
Study: 2683835

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 57

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 57
Study: 9963

Group type: EXPERIMENTAL
Intervention: N-desmethyldiazepam (nordiazepam) 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: N-desmethyldiazepam (nordiazepam) 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Potassium clorazepate 15 mg
Number of subjects: 6
Study: 7244391

Group type: EXPERIMENTAL
Intervention: Medical and rehabilitative therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 51
Study: 31094793

Group type: EXPERIMENTAL
Intervention: Low volume/high concentration (LVHC) - 0.1 mL·kg of 0.4% levobupivacaine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High volume/low concentration (HVLC) - 0.2 mL·kg of 0.2% levobupivacaine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (LVHC and HVLC)
Number of subjects: 70
Study: 28931169

Group type: EXPERIMENTAL
Intervention: Lifestyle educational package including face‐to‐face, phone and SMS counseling and a booklet in addition to routine postpartum training
Number of subjects: 220

Group type: COMPARATOR
Intervention: Routine postpartum training
Number of subjects: 220
Study: 26274346

Group type: EXPERIMENTAL
Intervention: Insulin infusion to control blood glucose (normoglycemia 80-110 mg/dL)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Hyperglycemia (control group)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Insulin infusion to control blood glucose (normoglycemia) in critically ill rabbits
Number of subjects: 405

Group type: COMPARATOR
Intervention: Hyperglycemia in critically ill rabbits (control group)
Number of subjects: 405
Study: 24377647

Group type: EXPERIMENTAL
Intervention: Immediate loop electrosurgical excision procedure (LEEP)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Directed biopsies (3-step group)
Number of subjects: 314
Study: 22546623

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Carvedilol 25 mg/day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 132

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 132
Study: 18635707

Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Immediate-release d-amphetamine sulphate 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17488143

Group type: EXPERIMENTAL
Intervention: Sildenafil (phosphodiesterase-5 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracavernosal injections of alprostadil (with or without papaverine and phentolamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penile prostheses implantation
Number of subjects: 0
Study: 15145093

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 611

Group type: COMPARATOR
Intervention: MT
Number of subjects: 611
Study: 11435337

Group type: EXPERIMENTAL
Intervention: Permanent dual-chamber cardiac pacing (DDD pacemaker with rate-drop response function)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Beta-blocker atenolol (100 mg once a day)
Number of subjects: 93
Study: 9579813

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 8117122

Group type: EXPERIMENTAL
Intervention: Curosurf (natural porcine surfactant)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Exosurf Neonatal (synthetic surfactant)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (initial static Crs >= 1.8 ml/cm H2O/m)
Number of subjects: 73
Study: 2841724

Group type: EXPERIMENTAL
Intervention: CO2‐mepivacaine 1%
Number of subjects: 26

Group type: COMPARATOR
Intervention: mepivacaine HCl 1%
Number of subjects: 26
Study: 31111882

Group type: EXPERIMENTAL
Intervention: Conventional scalpel gingivectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser-assisted gingivectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-surgical periodontal treatment (Control Group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatment groups (TGs)
Number of subjects: 60
Study: 31292176

Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheters (PICCs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subcutaneously tunnelled central catheters (Hickman‐type devices)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Totally implantable chest wall ports (Ports)
Number of subjects: 42
Study: 28035541

Group type: EXPERIMENTAL
Intervention: EAA plus leflflunomide and methotrexate (30 g/d)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (leflflunomide and methotrexate)
Number of subjects: 159
Study: 26285109

Group type: EXPERIMENTAL
Intervention: Lithium (500 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg, on demand)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 23839902

Group type: EXPERIMENTAL
Intervention: 1 g daily of n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 5835

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5835

Group type: EXPERIMENTAL
Intervention: n-3 PUFA levels
Number of subjects: 5835
Study: 21463170

Group type: EXPERIMENTAL
Intervention: Long-term psychoanalytic treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 19304891

Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat oral immediate‐release solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat solution delivered to the proximal small bowel via Enterion capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat solution delivered to the distal small bowel via Enterion capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat solution delivered to the colon via Enterion capsule
Number of subjects: 0
Study: 17176361

Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors (coxibs)
Number of subjects: 88116

Group type: EXPERIMENTAL
Intervention: Celecoxib, rofecoxib, etoricoxib, lumiracoxib
Number of subjects: 88116

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 88116

Group type: COMPARATOR
Intervention: Coxibs
Number of subjects: 88116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88116

Group type: COMPARATOR
Intervention: Non-selective NSAIDs
Number of subjects: 88116
Study: 15247569

Group type: EXPERIMENTAL
Intervention: Active warming with a carbon‐fiber electric heating blanket (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Passive warming with a woolen blanket (Group 2)
Number of subjects: 100
Study: 10329884

Group type: EXPERIMENTAL
Intervention: Upper position
Number of subjects: 49

Group type: COMPARATOR
Intervention: Lower position
Number of subjects: 49
Study: 8698959

Group type: EXPERIMENTAL
Intervention: Cognitive therapy focusing on interpersonal and developmental vulnerabilities
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive therapy with a developmental focus
Number of subjects: 30
Study: 1725198

Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg b.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Perindopril plus placebo
Number of subjects: 10
Study: 6129914

Group type: EXPERIMENTAL
Intervention: nitrazepam 5 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: temazepam 20 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study: 29481448

Group type: EXPERIMENTAL
Intervention: Cognitive fatigue task (AX continuous performance test) for 60 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Watching a video on trains for 60 minutes (control condition)
Number of subjects: 8